Literature DB >> 21666704

Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines.

Zhi-ming Wu1, Chun Dai, Ying Huang, Cui-fang Zheng, Qiong-zhu Dong, Guan Wang, Xiao-wen Li, Xiao-fei Zhang, Bin Li, Gang Chen.   

Abstract

AIM: To investigate the anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in hepatocellular carcinoma (HCC) cell lines.
METHODS: HCC cell lines BEL7402, SMMC-7721, MHCC97L, MHCC97H, and MHCCLM3 were used. HCC cells were treated with dsP21-322 (50 nmol/L), dsControl (50 nmol/L), siP21 (50 nmol/L), or mock transfection. The expression of p21 was detected using quantitative PCR and Western blot. The effects of RNA activation on HCC cells were determined using cell viability assays, apoptosis analyses and clonogenic survival assays. Western blot was also conducted to detect the expression of Bcl-xL, survivin, cleaved caspase-3, cleaved caspase-9 and cleaved PARP.
RESULTS: At 72 to 120 h following the transfection, dsP21-322 markedly inhibited the viability of HCC cells and clone formation. At the same times, dsP21-322 caused a significant increase in HCC cell apoptosis, as demonstrated with cytometric analysis. The phenomena were correlated with decreased expression levels of the anti-apoptotic proteins Bcl-xL, surviving, and increased expression of cleaved caspase-3, cleaved caspase-9 and cleaved PARP.
CONCLUSION: RNA-induced activation of p21 gene expression may have significant therapeutic potential for the treatment of hepatocellular carcinoma and other cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666704      PMCID: PMC4003122          DOI: 10.1038/aps.2011.28

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  31 in total

1.  Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.

Authors:  Patrick J Paddison; Amy A Caudy; Emily Bernstein; Gregory J Hannon; Douglas S Conklin
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

2.  Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas.

Authors:  A M Hui; Y Kanai; M Sakamoto; H Tsuda; S Hirohashi
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

Review 3.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.

Authors:  Andrei L Gartel; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

4.  Survivin promotes cell proliferation in human hepatocellular carcinoma.

Authors:  T Ito; K Shiraki; K Sugimoto; T Yamanaka; K Fujikawa; M Ito; K Takase; M Moriyama; H Kawano; M Hayashida; T Nakano; A Suzuki
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

5.  Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells.

Authors:  M Gorospe; X Wang; K Z Guyton; N J Holbrook
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

6.  Small interfering RNA-induced transcriptional gene silencing in human cells.

Authors:  Kevin V Morris; Simon W-L Chan; Steven E Jacobsen; David J Looney
Journal:  Science       Date:  2004-08-05       Impact factor: 47.728

7.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

8.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.

Authors:  S Waga; G J Hannon; D Beach; B Stillman
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

9.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

10.  RNAa is conserved in mammalian cells.

Authors:  Vera Huang; Yi Qin; Ji Wang; Xiaoling Wang; Robert F Place; Guiting Lin; Tom F Lue; Long-Cheng Li
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more
  7 in total

1.  Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.

Authors:  Mika Kosaka; Moo Rim Kang; Glen Yang; Long-Cheng Li
Journal:  Nucleic Acid Ther       Date:  2012-08-21       Impact factor: 5.486

2.  Reactivation of HIC-1 gene by saRNA inhibits clonogenicity and invasiveness in breast cancer cells.

Authors:  Feng Zhao; Shengli Pan; Yan Gu; Shanyu Guo; Qiancheng Dai; Yingyan Yu; Wei Zhang
Journal:  Oncol Lett       Date:  2014-10-24       Impact factor: 2.967

3.  MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1).

Authors:  H Wang; L-J Zhu; Y-C Yang; Z-X Wang; R Wang
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

4.  Autophagy-Related Gene Pairs Signature for the Prognosis of Hepatocellular Carcinoma.

Authors:  Yiming Luo; Furong Liu; Shenqi Han; Yongqiang Qi; Xinsheng Hu; Chenyang Zhou; Huifang Liang; Zhiwei Zhang
Journal:  Front Mol Biosci       Date:  2021-05-20

5.  Small double-stranded RNA mediates the anti-cancer effects of p21WAF1/ClP1 transcriptional activation in a human glioma cell line.

Authors:  Zhiqiang Dong; Yamei Dang; Yirong Chen
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

6.  miR-6734 Up-Regulates p21 Gene Expression and Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Cells.

Authors:  Moo Rim Kang; Ki Hwan Park; Jeong-Ook Yang; Chang Woo Lee; Soo Jin Oh; Jieun Yun; Myeong Youl Lee; Sang-Bae Han; Jong Soon Kang
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

Review 7.  Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments.

Authors:  Hossein Ghanbarian; Shahin Aghamiri; Mohamad Eftekhary; Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.